Di Zhe Pharmaceuticals: Stock price abnormal fluctuations with uncertainty in AstraZeneca transactions.

Dizhe Pharmaceuticals announced that the company's stock had a cumulative deviation from the closing price on July 13-15, 2026, reaching 30%, which is considered abnormal volatility. Recently, the company signed a licensing agreement with AstraZeneca, granting them the exclusive global rights to develop and commercialize Shuwozhe. AstraZeneca will pay an upfront fee of $600 million, up to $400 million in clinical development and $500 million in sales milestone payments, as well as royalties. This transaction is subject to shareholder approval, conditions being met, and obtaining relevant approvals, so there is uncertainty about its final effectiveness. The company reminds investors to be aware of the risks.